Will Feature SENSUS Pain Management System and DPNCheck Peripheral
Neuropathy Test
WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that
develops wearable medical technology and point-of-care tests to help
patients and physicians manage chronic pain, nerve diseases, and sleep
disorders, reported today that it will exhibit at the American Diabetes
Association's (ADA) 74th Scientific Sessions. The ADA
Scientific Sessions will be held on June 13-17 in San Francisco at the
Moscone Center.
NeuroMetrix, led by its President and Chief Executive Officer, Shai N.
Gozani, M.D., Ph.D., will feature the SENSUS™ Pain Management
System designed for people suffering from painful diabetic neuropathy
(PDN). This comfortable and wearable technology utilizes non-invasive
stimulation of sensory nerves to deliver a fast-acting, drug free option
for pain relief. The device is lightweight and can be worn during the
day while remaining active, or at night while sleeping. PDN is one of
the most common causes of chronic pain and affects up to 5 million
people in the U.S. alone. SENSUS is marketed in the U.S. by DJO Global
and by regional distributors.
DPNCheck® will also be featured. This rapid and quantitative
point-of-care test allows physicians to accurately detect diabetic
peripheral neuropathy (DPN), even at very early stages. DPN is the most
common complication of diabetes, affecting over half of people with
diabetes. DPN causes significant morbidity including loss of sensation,
pain, increased risk of falling in the elderly, and is the primary
trigger for diabetic foot ulcers which may require lower extremity
amputations. DPNCheck is directly marketed by NeuroMetrix in the U.S.
and by Omron Healthcare in the major markets of Asia.
The Company's scientific advisory board representing international
leaders in the detection, management, and treatment of the neurological
complications of diabetes will meet at the ADA Scientific Sessions.
Attendees are encouraged to visit NeuroMetrix at booth #1237.
About NeuroMetrix
NeuroMetrix is an innovative health-care
company that develops wearable medical technology and point-of-care
tests that help patients and physicians better manage chronic pain,
nerve diseases, and sleep disorders. The Company has a major focus on
diabetic neuropathies, which affect over 50% of people with diabetes. If
left untreated, diabetic neuropathies trigger foot ulcers that may
require amputation and cause disabling chronic pain. The annual cost of
diabetic neuropathies has been estimated at $14 billion in the United
States. The Company markets the SENSUS device for treating chronic pain,
focusing on physicians managing patients with neuropathic pain such as
painful diabetic neuropathy. The Company also markets DPNCheck, which is
a rapid, accurate, and quantitative point-of-care test for peripheral
neuropathies such as diabetic neuropathy. This product is used to detect
neuropathies at an early stage and to guide treatment. For more
information, please visit http://www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
